ASCO: Adding Curcuminoids to Docetaxel Shows Promise in Castration-Resistant Prostate Cancer
Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel “in terms of both PSA decrease and objective response” in a phase II trial in patients with castration-resistant prostate cancer. (Source: Cancer Network)
Source: Cancer Network - June 5, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Fewer Side Effects With Radiotherapy Alone for Some Node-Positive Breast Cancer Patients
A study presented at ASCO shows that axillary radiotherapy results in similar outcomes to axillary lymph node dissection, but halved the incidence of lymphedema. (Source: Cancer Network)
Source: Cancer Network - June 5, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Rapid, Durable Bone Met Pain Relief With MR Guided Focused Ultrasound
The use of magnetic resonance guided focused ultrasound ablation therapy for the management of painful bone metastases resulted in a high rate of pain response that was rapid, durable and clinically meaningful, according to an abstract presented at the 2013 ASCO Annual Meeting in Chicago. (Source: Cancer Network)
Source: Cancer Network - June 4, 2013 Category: Cancer & Oncology Source Type: news

ASCO: NSCLC Tumor Profiling and Biomarker-Guided Therapy are Feasible
A massive French database study shows that genetic tumor profiling in patients with non–small-cell lung cancer (NSCLC) is feasible, and is already helping physicians guide treatment in many patients, according to results presented at the American Society of Clinical Oncology annual meeting. (Source: Cancer Network)
Source: Cancer Network - June 4, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Enzalutamide Monotherapy in Prostate Cancer Achieves ‘High Response Rate, Marked PSA Decline'
Monotherapy with enzalutamide (Xtandi) achieved a “high PSA response rate and marked PSA decline” in patients with hormone-naïve prostate cancer after 6 months in a single-arm, multicenter phase II study. (Source: Cancer Network)
Source: Cancer Network - June 4, 2013 Category: Cancer & Oncology Source Type: news

ASCO: NSCLC Therapy Guided by RRM1, ERCC1 Expression Yields No Survival Difference
Guiding treatment for non–small-cell lung cancer (NSCLC) using expression levels of the proteins RRM1 and ERCC1 led to no difference in either progression-free or overall survival, according to a study presented at the American Society of Clinical Oncology (ASCO) annual meeting. (Source: Cancer Network)
Source: Cancer Network - June 4, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
Women diagnosed with estrogen-receptor (ER)-positive breast cancer who took tamoxifen for 10 years as adjuvant therapy had lower risk of late recurrence and lower risk of death compared to those who took the drug for 5 years. These results corroborate the findings of the international ATLAS trial. (Source: Cancer Network)
Source: Cancer Network - June 3, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
Treatment with 200 µmol per day of sulforaphane for 20 weeks was “feasible, safe,” and inhibited histone deacetylase (HDAC) function in a single-arm study of 20 patients who had non-castrate biochemical (PSA)-recurrence of prostate cancer despite surgery or radiation. (Source: Cancer Network)
Source: Cancer Network - June 3, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Pomalidomide New Standard of Care in Heavily Pretreated, Relapsed Multiple Myeloma
Pomalidomide in combination with low-dose dexamethasone had a highly significant benefit on progression-free survival and overall survival compared with single-agent high-dose dexamethasone in patients with relapsed or refractory multiple myeloma, according to updated results of the MM-03 trial presented at the ASCO 2013 Annual Meeting. (Source: Cancer Network)
Source: Cancer Network - June 3, 2013 Category: Cancer & Oncology Source Type: news

ASCO: For Painful Bone Mets, Single Fraction Irradiation Noninferior to Multiple-Fraction Therapy
The use of a single 8 Gy fraction of re-irradiation for the treatment of painful bone metastases was noninferior to multiple fractions, according to the results of the NCIC CTG SC.20 trial presented at the ASCO 2013 Annual Meeting in Chicago. (Source: Cancer Network)
Source: Cancer Network - June 3, 2013 Category: Cancer & Oncology Source Type: news

ASCO: DNR Completion at End of Life Influenced by Perception of Caregiver Support
Results of a new study indicated that patients with terminal cancer are more likely to have completed a do-not-resuscitate order when they prefer, and believe that their caregiver prefers, comfort at the end of life. (Source: Cancer Network)
Source: Cancer Network - June 3, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Prolonged Survival in Multiple Myeloma Predicted Using Deep Sequencing
Multiparameter flow cytometry and deep sequencing were both able to accurately identify patients with multiple myeloma who were negative for minimal residual disease, a factor that was found to better predict prolonged survival compared with complete response as measured by traditional response criteria. (Source: Cancer Network)
Source: Cancer Network - June 3, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Preview of the Prostate Cancer Sessions
Ahead of the 2013 ASCO meeting we highlight some of this year's prostate cancer sessions, many of which focus on how best to use the new agents that have been approved recently, and look into the new drugs and combinations being presented from early trials. (Source: Cancer Network)
Source: Cancer Network - May 30, 2013 Category: Cancer & Oncology Source Type: news

Study: Recurrent Heartburn Ups Risk for Throat Cancer
A new population-based study of never-smokers shows those with gastric reflux are more likely to be diagnosed with cancers of the throat, including the voice box. (Source: Cancer Network)
Source: Cancer Network - May 29, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Neoadjuvant Therapy Options and Clinical Trials in Breast Cancer
Ahead of the ASCO 2013 meeting we discuss neoadjuvant therapy options and clinical trials in breast cancer, as well as the opportunities for targeted therapies in post-neoadjuvant trials. (Source: Cancer Network)
Source: Cancer Network - May 29, 2013 Category: Cancer & Oncology Source Type: news

Cannabis Linked to Decreased Bladder Cancer Risk
The use of cannabis among men has been linked to a significantly decreased risk for bladder cancer, according to a recent study; however, no cause and effect association has been found. (Source: Cancer Network)
Source: Cancer Network - May 28, 2013 Category: Cancer & Oncology Source Type: news

AUA Guidelines for Metastatic Castration-Resistant Prostate Cancer
The AUA recently released its first set of treatment guidelines addressing the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) at its 2013 Annual Meeting. The guidelines were released to address the increasingly complex treatment landscape available for patients with mCRPC. (Source: Cancer Network)
Source: Cancer Network - May 28, 2013 Category: Cancer & Oncology Source Type: news

Conservative vs Aggressive Treatment in Older Prostate Cancer Patients
Survival data of prostate cancer patients 70 and older show that those with three or more comorbidities and low- or intermediate-risk prostate cancer are less likely to die from prostate cancer than another health issue. But those with aggressive, high-risk disease are more likely to die from their prostate cancer. (Source: Cancer Network)
Source: Cancer Network - May 28, 2013 Category: Cancer & Oncology Source Type: news

Breast Cancer Screening, Risk, and Options for High-Risk Women
We speak with two experts to discuss breast cancer risk, genetics, and prevention options available to women at high risk of developing breast and ovarian cancer. (Source: Cancer Network)
Source: Cancer Network - May 23, 2013 Category: Cancer & Oncology Source Type: news

A 52-Year-Old Man Presents With an Erythematous Lesion
A 52-year-old man presented with an erythematous lesion in the axilla of unknown duration. Surgical excision was performed. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - May 22, 2013 Category: Cancer & Oncology Source Type: news

Colorectal Cancer Treatments and Therapy Innovations
In this interview we discuss the advances in treatment for colorectal cancer, as well as ongoing developments to find new and better therapies to treat this type of cancer. (Source: Cancer Network)
Source: Cancer Network - May 22, 2013 Category: Cancer & Oncology Source Type: news

Bone Metastases
This slide show features images of diffuse osteoblastic bone metastases in a 70-year-old advanced prostate cancer patient, bone metastases in the vertebral column of a kidney cancer patient, and more. (Source: Cancer Network)
Source: Cancer Network - May 21, 2013 Category: Cancer & Oncology Source Type: news

Obesity Impairs Efficacy of L-Asparaginase in Leukemia Treatment
Findings suggesting that obesity substantially impairs the ability of L-asparaginase to kill leukemia cells were reported last month by investigators from The Saban Research Institute, Children’s Hospital Los Angeles. (Source: Cancer Network)
Source: Cancer Network - May 20, 2013 Category: Cancer & Oncology Source Type: news

Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
A large study shows that middle-age men engaged in lots of cardiovascular exercise have a reduced risk of developing and dying from lung and colorectal cancer. (Source: Cancer Network)
Source: Cancer Network - May 20, 2013 Category: Cancer & Oncology Source Type: news

Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Palliative radiotherapy is an effective means of alleviating pain and improving overall quality of life in elderly patients with bone metastases, according to a new study. (Source: Cancer Network)
Source: Cancer Network - May 20, 2013 Category: Cancer & Oncology Source Type: news

New AUA Guidelines for Prostate Cancer Screening
The American Urological Association (AUA) released a new clinical guideline detailing recommendations for the use of prostate cancer screening in average-risk men based upon evidence from a systematic literature review. The guideline, which was announced during the 2013 AUA Annual Meeting, recommends that men aged 55 to 69 years who are considering undergoing prostate cancer screening should talk with their physicians about the benefits and risks of screening. (Source: Cancer Network)
Source: Cancer Network - May 19, 2013 Category: Cancer & Oncology Source Type: news

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis? (Source: Cancer Network)
Source: Cancer Network - May 17, 2013 Category: Cancer & Oncology Source Type: news

Genomics Studies Identify Testicular Cancer Risk Variants
Two genome-wide studies have identified a total of 12 new genetic loci associated with a higher risk of testicular cancer. The risk-associated genetic variations could help clinicians single out higher-risk men for screening and early detection. (Source: Cancer Network)
Source: Cancer Network - May 17, 2013 Category: Cancer & Oncology Source Type: news

50 Shades of Pink—And Why It Helps to Know the Difference
Buy toxic chemicals and support breast cancer research! Not lying—just saw an ad on TV for weed killer and it had a pink ribbon logo on its packaging indicating, “A portion of every sale goes to support breast cancer research and awareness.” We have plenty of weed killer and a perfect lawn at our house, so I am no critic of the product. But have you noticed the pink ribbon logo on virtually every conceivable item or service? (Source: Cancer Network)
Source: Cancer Network - May 17, 2013 Category: Cancer & Oncology Source Type: news

Statin Use Improved Survival Post-Nephrectomy for RCC
The use of statins was independently associated with improvements in overall survival and disease-specific survival among a group of patients who had undergone partial or radical nephrectomy for renal cell carcinoma. (Source: Cancer Network)
Source: Cancer Network - May 16, 2013 Category: Cancer & Oncology Source Type: news

Radium-223 Gets Early FDA Nod for Bone Mets in Castration-Resistant Prostate Cancer
Radium-223 dichloride (Xofigo) received FDA approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has metastasized to the bone but no other organs. (Source: Cancer Network)
Source: Cancer Network - May 16, 2013 Category: Cancer & Oncology Source Type: news

FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
The FDA approved a label expansion for erlotinib (Tarceva), along with the cobas EGFR mutation diagnostic test, to include patients untreated metastatic NSCLC patients whose tumors have either a deletion in exon 19 or exon 21 (L858R) substitution mutations in the EGFR gene. (Source: Cancer Network)
Source: Cancer Network - May 16, 2013 Category: Cancer & Oncology Source Type: news

Introducing Three New Features
No doubt you’ve already been struck by how different the cover of this issue of ONCOLOGY looks. We hope you like our new look! More importantly, we hope you’ll like the new features we've added. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

How the Sequester Cuts Are Harming Oncology
Now is a critical moment for all involved in caring for cancer patients to engage in this national policy debate; numerous cancer advocacy organizations have already joined the effort to oppose the sequester cuts to oncology drugs. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Secondary Hormone Therapy for Castration-Resistant Prostate Cancer
The majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant prostate cancer (CRPC). (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Advances in the Systemic Treatment of Metastatic Melanoma
Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Rising PSA Level in a 46-Year-Old Man
A 46-year-old man sought consultation for an abnormal prostate-specific antigen (PSA) level of 9 ng/mL and one prior negative biopsy. Five months ago, while traveling, he had presented to an urgent care facility with a 24-hour history of fever, chills, nausea, and vomiting. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

New Targets and New Mechanisms in Lung Cancer
This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Making Good Results Even Better: The Evolving Role of Radiotherapy in Patients With Early Diffuse Large B-Cell Lymphoma
If systemic treatment is effective enough to reliably control not only microscopic but also bulky disease, there will be little role for radiotherapy. And if systemic treatment cannot even reliably control microscopic disease, let alone macroscopic disease, there will be little role for radiotherapy, either. However, there are patients who fall into neither of these categories, and in them radiotherapy may well have a role. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Radiotherapy Is NOT Essential to Cure Diffuse Large B-Cell Non-Hodgkin Lymphoma
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Cancer Metabolism as a Therapeutic Target
Ongoing studies are attempting to understand the reasons that tumor cells engage in aerobic glycolysis in lieu of oxidative phosphorylation. In this review, we discuss known benefits to tumor cells from this metabolic switch, and we highlight key enzymes that play a role in aerobic glycolysis. We also describe novel therapeutic options targeting glucose metabolism. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Don't Tell Me Anything Negative
I looked after one of my partner’s patients who is approaching death from advanced, refractory ovarian cancer. She asked me not to talk about anything negative with her. We can’t really make any decisions without discussing negative things. Should I just remain silent about them at her request? (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
A cohort-based study found that men with prostate cancer who took cholesterol-lowering statins had a lower risk of dying from their prostate cancer. (Source: Cancer Network)
Source: Cancer Network - May 14, 2013 Category: Cancer & Oncology Source Type: news

In NSCLC, Beta-3 Tubulin Isoform Does Not Predict Treatment Response to Ixabepilone, Paclitaxel
Expression of the beta-3 tubulin (ß3T) isoform was a negative prognostic factor in non–small-cell lung cancer (NSCLC) patients, but did not predict treatment response for either paclitaxel or tubulin-inhibiting chemotherapy with ixabepilone. (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news

A 49-Year-Old Woman Develops Thickened and Bound-Down Skin
A 49-year-old woman insidiously developed spotty depigmentation of the chest along with thickened and bound-down skin of the upper torso. In addition, all of her fingers were swollen and her facial skin became so tight that she had difficulty smiling. What is her diagnosis? (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news

It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
Recently published research questions the need for the advised restriction against the use of soyfoods by women with a history of breast cancer. (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news

Nilotinib Associated With Increased Peripheral Artery Disease Rate in CML
Two studies found higher rates of peripheral artery occlusive disease in nilotinib-treated chronic myeloid leukemia patients than in imatinib-treated patients. (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news

At Increased Cost, Robotic Partial Nephrectomy Improves Kidney Cancer Outcomes
A study found that robotic partial nephrectomy to remove kidney cancer tumors resulted in better outcomes, but also had significantly higher hospital charges. The data were presented at the annual meeting of the American Urological Association. (Source: Cancer Network)
Source: Cancer Network - May 10, 2013 Category: Cancer & Oncology Source Type: news

HERA Trial: Invasive Lobular Breast Carcinoma Patients Derived Same Benefit From Trastuzumab Maintenance
In the HERA trial, benefit for invasive lobular breast cancer patients with 1 year of trastuzumab maintenance was similar to invasive ductal carcinoma patients. (Source: Cancer Network)
Source: Cancer Network - May 7, 2013 Category: Cancer & Oncology Source Type: news

Parotid Gland Swelling in 45-Year-Old Patient
A 45-year-old man presented with swelling of the parotid gland. At physical examination a mass at the level of the parotid gland was found. Surgical resection of the mass was performed. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news